ACORN BIOVENTURES, L.P. 13D and 13G filings for Cyclacel Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-07 5:03 pm Sale | 2023-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | ACORN BIOVENTURES, L.P. | 0 0.000% | -187,676 (Position Closed) | Filing |
| 2023-01-26 1:36 pm Purchase | 2022-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | ACORN BIOVENTURES, L.P. | 187,676 9.990% | 31,377 (+20.07%) | Filing |
| 2021-02-12 4:58 pm Purchase | 2020-12-18 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | ACORN BIOVENTURES, L.P. | 156,299 9.990% | 156,299 (New Position) | Filing |